Stentrode BCI System
Severe Paralysis (e.g., from ALS, stroke, spinal cord injury)
Early Feasibility StudyActive
Key Facts
Indication
Severe Paralysis (e.g., from ALS, stroke, spinal cord injury)
Phase
Early Feasibility Study
Status
Active
Company
About Synchron
Synchron is pioneering a minimally invasive brain-computer interface platform that aims to restore autonomy to people with severe paralysis. Its flagship technology, the Stentrode, is implanted via blood vessels, offering a safer alternative to open-brain surgery BCIs. The company is actively conducting clinical trials in the US and Australia and has secured significant funding and a Breakthrough Device designation from the FDA. Synchron is positioned as a leading contender in the emerging neurotechnology market, competing to bring the first commercially viable BCI to patients.
View full company profile